Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Feasibility Study of TimoD Implant in Glaucoma or Ocular Hypertension
NCT07036510Phase 2Recruiting
- Sponsor
- EyeD Pharma
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of timolol in Glaucoma and ocular hypertension (4 arms), sponsored by EyeD Pharma. Primary endpoints: Adverse Events at Month 13, Adverse Events of Special Interest at Month 13 and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
timolol
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT07036510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07036510.